Fund 3 Veteran-Led Vironexis
1 known investors
Vironexis is a clinical-stage biotechnology company developing an in vivo protein engineering platform called TransJoin, which uses non-integrating AAV vectors to instruct a patient's liver to continuously secrete bispecific T-cell engagers from a single IV dose. Its pipeline targets hematologic malignancies, solid tumors, and immune disorders, with lead candidates VNX-101 (CD19+ leukemias and lymphomas) and VNX-202 (HER2+ cancers) in Phase 1/2 clinical trials.